RVL Pharmaceuticals plc Ordinary Shares
RVLP
RVLP was delisted on the 20th of October, 2023.
36 hedge funds and large institutions have $13.5M invested in RVL Pharmaceuticals plc Ordinary Shares in 2023 Q2 according to their latest regulatory filings, with 1 funds opening new positions, 4 increasing their positions, 13 reducing their positions, and 6 closing their positions.
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
12% less funds holding
Funds holding: 41 → 36 (-5)
53% less capital invested
Capital invested by funds: $28.7M → $13.5M (-$15.2M)
69% less repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 13
83% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 6
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$16.1K |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$8.96K |
| 3 |
TRCT
Tower Research Capital (TRC)
New York
|
+$1.88K |
| 4 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$827 |
| 5 |
Wells Fargo
San Francisco,
California
|
+$9 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Scoggin Management
New York
|
-$300K |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$146K |
| 3 |
ACM
AIGH Capital Management
Baltimore,
Maryland
|
-$123K |
| 4 |
Millennium Management
New York
|
-$121K |
| 5 |
ACH
ArrowMark Colorado Holdings
Denver,
Colorado
|
-$103K |
RVLP Hedge Fund Activity: Q2 2023 in Review
36 of the 6,370 institutional investors tracked by Wall St. Rank reported a position in RVL Pharmaceuticals plc Ordinary Shares (RVLP) for Q2 2023, worth a combined $13.5M — down 53% from $28.7M a quarter earlier.
Sellers outnumbered buyers: 6 funds closed out of RVLP and 1 opened new positions — a net loss of 5 holders — while 13 trimmed existing stakes and 4 added.
The largest buyer was BlackRock, adding an estimated $16.1K. The largest seller was Scoggin Management, cutting an estimated $300K.
- 36 institutional investors held RVL Pharmaceuticals plc Ordinary Shares (RVLP) as of Q2 2023, down from 41 in Q1 2023.
- Funds reported $13.5M of RVL Pharmaceuticals plc Ordinary Shares stock for Q2 2023, down 53% quarter-over-quarter.
- 1 fund opened new RVL Pharmaceuticals plc Ordinary Shares positions in Q2 2023 and 6 closed out, a net change of -5 holders.
- The largest RVL Pharmaceuticals plc Ordinary Shares buyer in Q2 2023 was BlackRock, an estimated $16.1K added.
- The largest RVL Pharmaceuticals plc Ordinary Shares seller in Q2 2023 was Scoggin Management, an estimated $300K sold.
Based on aggregated 13F filings for Q2 2023.